Get the Stockscreener App
22.94
0.26%
-0.06
After Hours:
22.94
Pulse Biosciences Inc stock is traded at $22.94, with a volume of 309.14K.
It is down -0.26% in the last 24 hours and up +26.46% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$23.00
Open:
$23.02
24h Volume:
309.14K
Relative Volume:
0.95
Market Cap:
$1.56B
Revenue:
$350.00K
Net Income/Loss:
$-72.78M
P/E Ratio:
-21.24
EPS:
-1.08
Net Cash Flow:
$-54.46M
1W Performance:
+16.86%
1M Performance:
+26.46%
6M Performance:
+17.94%
1Y Performance:
+52.12%
1-Day Range:
$22.64
$23.48
1-Week Range:
$19.98
$23.66
52-Week Range:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
22.94 | 1.56B | 350.00K | -72.78M | -54.46M | -1.08 |
ISRG
Intuitive Surgical Inc
|
452.58 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.32 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.63 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
43.88 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
224.93 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
PLSE SEC FilingsPulse Biosciences Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Aug Swings: Is Pulse Biosciences Inc exposed to currency risks2026 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn
How Pulse Biosciences Inc (PLSE) Affects Rotational Strategy Timing - Stock Traders Daily
Pulse Biosciences (PLSE) awards CTO 100,000 Restricted Stock Units - stocktitan.net
Pulse Biosciences, Inc. (PLSE) stock price, news, quote and history - Yahoo Finance Australia
Pulse Biosciences, Inc. (PLSE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference - businesswire.com
Pulse Biosciences Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Pulse Biosciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q4 2025 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
Q3 2025 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
Q1 2025 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
PLSE accelerates cardiac catheter program after breakthrough AFib data - MSN
Pulse Biosciences Shifts Focus to Catheter Electrophysiology Tech - Medical Product Outsourcing
How Pulse Biosciences’ nPulse AFib Refocus Will Impact Pulse Biosciences (PLSE) Investors - simplywall.st
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7%What's Next? - marketbeat.com
PLSE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pulse Biosciences, Inc. 8-K SEC Filing March 23, 2026 – Company Information, NASDAQ Listing, and Key Details - Minichart
Pulse Biosciences Grants RSUs to Chief Technology Officer - TipRanks
Pulse Biosciences (NASDAQ: PLSE) awards CTO 100,000-share RSU grant - Stock Titan
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data - sharewise.com
PLSE Speeds Up Cardiac Catheter Initiative Following Landmark AFib Findings - Bitget
Stock Analysis: Is Pulse Biosciences Inc exposed to currency risks2026 Short Interest & Risk Managed Trade Strategies - baoquankhu1.vn
(PLSE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pulse Biosciences to accelerate Pulse Cardiac Catheter Ablation System - msn.com
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot - Sahm
Pulse Biosciences Touts 96% 12-Month Rhythm Control, Targets Q2 Start for U.S. AF IDE Study - Yahoo Finance
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
What's Going With Pulse Biosciences Stock On Monday? - MSN
Pulse Biosciences targets CE mark submission in 2026 as nPulse platform advances clinical milestones - MSN
Pulse Biosciences at Oppenheimer Conference: Promising AF Ablation Results By Investing.com - Investing.com India
Pulse Biosciences (NASDAQ:PLSE) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Pulse Biosciences shifts focus to cardiac catheter program By Investing.com - Investing.com South Africa
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter PlatformHas The Bull Case Changed? - simplywall.st
Pulse Biosciences Announces Organizational Realignment to Accelerate Cardiac Catheter Program After Exceptional AFib Clinical Results - Minichart
Pulse Biosciences Realigns Strategy Around nPulse AFib Platform - TipRanks
Pulse Biosciences (PLSE) realigns strategy around nPulse AFib catheter program - Stock Titan
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data - BioSpace
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program - marketscreener.com
Pulse Biosciences (PLSE) Prioritizes nPulse Cardiac Catheter Dev - GuruFocus
Pulse Biosciences shifts focus to cardiac catheter program - Investing.com
Is Pulse Biosciences’ (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy? - Yahoo Finance
A Look At Pulse Biosciences (PLSE) Valuation As Thyroid Cancer Feasibility Study Begins - Yahoo Finance
Pulse Biosciences enrolls first patients in thyroid cancer study - Investing.com Nigeria
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And DCF Estimate Gap - simplywall.st
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):